Synta Pharma (SNTA) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Roth Capital Positive on Synta (SNTA) Following Q3 Results; Focus Remains on Ganetespib Phase III GALAXY-2
November 6, 2014 2:09 PM ESTRoth Capital affirms Synta Pharma (Nasdaq: SNTA) at Buy with a price target of $27 following Q3 results reported earlier on the session.
Synta Pharma reported Q3 loss of $0.19 per share, $0.05 better than the analyst loss estimate of $0.24 per share.
Analyst Joseph Pantginis noted that Synta announced the... More
